omeprazole has been researched along with Seizures in 7 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Seizures: Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Two cases of severe hypomagnesaemia in adult long-term users of the PPI omeprazole, presenting with hypocalcaemic seizures." | 3.74 | Severe hypomagnesaemia in long-term users of proton-pump inhibitors. ( Cundy, T; Dissanayake, A, 2008) |
| "Omeprazole has long been used as an effective agent to treat peptic ulcer." | 1.31 | Anticonvulsant activity of omeprazole in rats. ( Balakrishnan, S; Bhargava, VK; Pandhi, P, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Semb, S | 1 |
| Helgstrand, F | 1 |
| Hjørne, F | 1 |
| Bytzer, P | 1 |
| Platt, S | 1 |
| Fukushima, Y | 1 |
| Shindo, T | 1 |
| Anai, M | 1 |
| Saitoh, T | 1 |
| Wang, Y | 1 |
| Fujishiro, M | 1 |
| Ohashi, Y | 1 |
| Ogihara, T | 1 |
| Inukai, K | 1 |
| Ono, H | 1 |
| Sakoda, H | 1 |
| Kurihara, Y | 1 |
| Honda, M | 1 |
| Shojima, N | 1 |
| Fukushima, H | 1 |
| Haraikawa-Onishi, Y | 1 |
| Katagiri, H | 1 |
| Shimizu, Y | 1 |
| Ichinose, M | 1 |
| Ishikawa, T | 1 |
| Omata, M | 1 |
| Nagai, R | 1 |
| Kurihara, H | 1 |
| Asano, T | 1 |
| Cundy, T | 1 |
| Dissanayake, A | 1 |
| Giraud, V | 1 |
| Sée, J | 1 |
| Biour, M | 1 |
| Pras, V | 1 |
| Grangé, JD | 1 |
| Bodin, F | 1 |
| Kakinoki, B | 1 |
| Ono, C | 1 |
| Yamazaki, N | 1 |
| Chikamatsu, N | 1 |
| Wakatsuki, D | 1 |
| Uchiyama, K | 1 |
| Morinaka, Y | 1 |
| Balakrishnan, S | 1 |
| Bhargava, VK | 1 |
| Pandhi, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacodynamic Dose-Response of S-Tenatoprazole-Na (STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers[NCT00284908] | Phase 1 | 32 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Assessment of the Healing Rate of Erosive or Ulcerative Esophagitis After Two and Four Weeks of Treatment With S-Tenatoprazole-Na (STU-Na) 15 mg, 30 mg, 60 mg, 90 mg and Esomeprazole 40 mg. A Multicenter, Randomized, Double-Blind, Parallel Group Study.[NCT00282555] | Phase 2 | 450 participants | Interventional | 2006-02-28 | Suspended | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 other studies available for omeprazole and Seizures
| Article | Year |
|---|---|
Persistent severe hypomagnesemia caused by proton pump inhibitor resolved after laparoscopic fundoplication.
Topics: Administration, Oral; Aged; Fundoplication; Gastroesophageal Reflux; Humans; Infusions, Intravenous; | 2017 |
Altered states of consciousness in small animals.
Topics: Adrenal Cortex Hormones; Algorithms; Animals; Anticonvulsants; Behavior, Animal; Brain Diseases; Flu | 2014 |
Structural and functional characterization of gastric mucosa and central nervous system in histamine H2 receptor-null mice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Blotting, Northern; Electroshock; Gastric Acid; Ga | 2003 |
Severe hypomagnesaemia in long-term users of proton-pump inhibitors.
Topics: Aged; Female; Gastroesophageal Reflux; Humans; Hypocalcemia; Magnesium Deficiency; Male; Middle Aged | 2008 |
[Generalized convulsive crisis during the intravenous administration of omeprazole at high doses].
Topics: Aged; Aged, 80 and over; Female; Gastrointestinal Hemorrhage; Humans; Injections, Intravenous; Omepr | 1994 |
General pharmacological properties of the new proton pump inhibitor (+/-)-5-methoxy-2-[[(4-methoxy-3,5-dimethylpyrid-2-yl)methyl]sulf inyl]- 1H-imidazo[4,5-b]pyridine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Dogs; Guinea Pigs; Ileum; Imida | 1999 |
General pharmacological properties of the new proton pump inhibitor (+/-)-5-methoxy-2-[[(4-methoxy-3,5-dimethylpyrid-2-yl)methyl]sulf inyl]- 1H-imidazo[4,5-b]pyridine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Dogs; Guinea Pigs; Ileum; Imida | 1999 |
General pharmacological properties of the new proton pump inhibitor (+/-)-5-methoxy-2-[[(4-methoxy-3,5-dimethylpyrid-2-yl)methyl]sulf inyl]- 1H-imidazo[4,5-b]pyridine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Dogs; Guinea Pigs; Ileum; Imida | 1999 |
General pharmacological properties of the new proton pump inhibitor (+/-)-5-methoxy-2-[[(4-methoxy-3,5-dimethylpyrid-2-yl)methyl]sulf inyl]- 1H-imidazo[4,5-b]pyridine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Dogs; Guinea Pigs; Ileum; Imida | 1999 |
Anticonvulsant activity of omeprazole in rats.
Topics: Animals; Anticonvulsants; Brain; Carbonic Anhydrase Inhibitors; Drug Tolerance; Electroshock; Enzyme | 2001 |